Pharmacogenetics of post-transplant diabetes mellitus in children with renal transplantation treated with tacrolimus.
Lancia, Pauline; Adam de Beaumais, Tiphaine; Elie, Valéry; Garaix, Florentine; Fila, Marc; Nobili, François; Ranchin, Bruno; Testevuide, Pascale; Ulinski, Tim; Zhao, Wei; Deschênes, Georges; Jacqz-Aigrain, Evelyne.
; 33(6): 1045-1055, 2018 06.
Artigo em Inglês | MEDLINE | ID: mdl-29399716
CYP3A4 and GCK genetic polymorphisms are the risk factors of tacrolimus-induced new-onset diabetes after transplantation in renal transplant recipients.
Weight of ABCB1 and POR genes on oral tacrolimus exposure in CYP3A5 nonexpressor pediatric patients with stable kidney transplant.
Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation.
Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients.
Population pharmacokinetic and pharmacogenetic analysis of tacrolimus in paediatric liver transplant patients.
[Effect of CYP3A4*18B, CYP3A5*3 gene polymorphism on dosage and concentration of tacrolimus in renal transplant patients].
Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-α are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus.
Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Survival Time to Biopsy-Proven Acute Rejection and Tacrolimus Adverse Drug Reactions in Pediatric Liver Transplantation.
Impact of POR and CYP3A5 Polymorphisms on Trough Concentration to Dose Ratio of Tacrolimus in the Early Post-operative Period Following Kidney Transplantation.